Skip to main content

Table 1 Baseline clinical characteristics of the study population

From: Triglyceride glucose index combined with plaque characteristics as a novel biomarker for cardiovascular outcomes after percutaneous coronary intervention in ST-elevated myocardial infarction patients: an intravascular optical coherence tomography study

Variables Total (N = 274) Plaque erosion (N = 119) Plaque rupture (N = 155) P value
Age (years) 58.0 (50.0, 67.0) 56.0 (50.0, 65.5) 60.0 (50.0, 67.5) 0.054
Male [%(n)] 221 (80.7) 93 (78.2) 128 (82.6) 0.444
Height (cm) 170.0 (165.0, 173.0) 169.0 (165.0, 173.0) 170.0 (165.0, 173.8) 0.296
Weight (kg) 75.0 (67.0, 82.2) 75.0 (67.0, 80.0) 75.0 (67.2, 84.0) 0.220
Heart rate (beats per minute) 76.0 (65.0, 86.0) 78.0 (66.0, 87.8) 75.0 (65.0, 85.0) 0.357
SBP (mmHg) 121.0 (107.0, 134.0) 120.0 (109.0, 128.8) 122.0 (106.5, 135.5) 0.419
DBP(mmHg) 79.0 ± 12.3 78.9 ± 12.4 79.0 ± 12.4 0.978
Syntax score of base 16.0 (11.0, 22.5) 15.5 (10.0, 22.0) 16.5 (11.0, 22.8) 0.372
Residual syntax score 4.0 (0.0, 8.0) 2.0 (0.0, 7.0) 5.0 (2.0, 9.0) 0.006*
Risk factors     
 Hypertension[%(n)] 164 (59.9) 70 (58.8) 94 (60.6) 0.857
 Diabetes[%(n)] 78 (28.5) 28 (23.5) 50 (32.3) 0.147
 Hyperlipidemia[%(n)] 236 (86.1) 99 (83.2) 137 (88.4) 0.291
 Smoking[%(n)] 165 (68.2) 66 (64.1) 99 (71.2) 0.298
 Previous PCI[%(n)] 22 ( 8.0) 6 (5) 16 (10.3) 0.171
 CKD[%(n)] 4 ( 1.6) 0 (0) 4 (2.8) 0.138
Laboratory examinations     
 HDL-cholesterol (mmol/L) 1.1 (0.9, 1.2) 1.1 (1.0, 1.2) 1.1 (0.9, 1.2) 0.177
 LDL-cholesterol at (mmol/L) 2.8 ± 0.9 2.8 ± 0.9 2.8 ± 0.8 0.906
 Triglycerides (mmol/L) 1.4 (1.0, 2.0) 1.4 (0.9, 2.0) 1.4 (1.0, 2.1) 0.681
 LPA (mg/L) 159.1 (71.5, 376.1) 181.0 (65.0, 439.2) 141.0 (75.8, 345.1) 0.282
 hs-CRP (mg/L) 6.2 (2.7, 10.9) 6.7 (3.2, 10.9) 5.8 (2.2, 10.9) 0.212
 D-dimer (ug/mL) 0.3 (0.2, 0.4) 0.3 (0.2, 0.4) 0.3 (0.2, 0.4) 0.937
 TnI (ng/L) 0.9 (0.1, 5.2) 1.5 (0.1, 5.2) 0.4 (0.1, 4.6) 0.041
 Peak level of TnI (ng/L) 23.9 (10.8, 46.5) 26.0 (11.3, 49.0) 22.0 (9.7, 41.5) 0.152
 BNP (ng/L) 137.3 (47.9, 566.0) 224.5 (75.6, 717.2) 103.0 (39.5, 416.2) 0.024*
 Peak level of BNP (ng/L) 1606.0 (633.5, 3122.0) 1463.0 (607.2, 2946.0) 1657.0 (673.8, 3179.0) 0.544
 WBC 109/L 9.8 (8.0, 11.9) 10.1 (8.1, 12.7) 9.6 (7.9, 11.4) 0.071
 Hemoglobin (g/L) 147.5 (136.0, 156.0) 149.0 (136.0, 155.0) 146.0 (135.0, 156.5) 0.603
 Platelet 109/L 222.0 (191.2, 280.8) 241.0 (198.0, 295.5) 212.0 (187.0, 266.0) 0.007*
 Crea (umol/L) 79.0 (67.9, 91.8) 75.8 (65.1, 89.5) 82.3 (70.6, 94.1) 0.005
 Fasting plasma glucose (mmol/L) 7.6 (6.3, 10.0) 7.5 (6.3, 9.8) 7.7 (6.3, 10.2) 0.351
 A1C (%) 6.0 (5.6, 7.1) 6.0 (5.6, 6.8) 6.0 (5.6, 7.4) 0.408
 TYGa 4.7 ± 0.7 4.6 ± 0.7 4.7 ± 0.8 0.410
TYG index tertiles     
 T1, n (%) 3.9 ± 0.3 3.9 ± 0.3 -
 T2, n (%) 4.6 ± 0.2 4.6 ± 0.2 -
 T3, n (%) 5.5 ± 0.5 5.3 ± 0.4 -
Discharge medication regimen     
 Aspirin[%(n)] 265 (96.7) 116 (97.5) 149 (96.1) 0.736
 Ticagrelor[%(n)] 139 (50.7) 53 (44.5) 86 (55.5) 0.094
 Clopidogrel[%(n)] 135 (49.3) 66 (55.5) 69 (44.5) 0.094
 ACEI/ARB[%(n)] 204 (74.5) 86 (72.3) 118 (76.1) 0.558
 Beta-Blockers[%(n)] 240 (87.6) 103 (86.6) 137 (88.4) 0.786
 Statin[%(n)] 266 (97.1) 116 (97.5) 150 (96.8) 1.000
 Proton pump inhibitor[%(n)] 109 (39.8) 52 (43.7) 57 (36.8) 0.300
 Oral anticoagulants[%(n)] 6 ( 2.2) 4 (3.4) 2 (1.3) 0.408
Procedural data     
Angiographic findings     
 Culprit vessels     0.002*
 LAD 131 (47.8) 65 (54.6) 66 (42.6)  
 LCX 27 ( 9.9) 17 (14.3) 10 (6.5)  
 RCA 116 (42.3) 37 (31.1) 79 (51)  
Coronary artery lesions     0.012*
 SVD 66 (24.1) 39 (32.8) 27 (17.4)  
 DVD 100 (36.5) 40 (33.6) 60 (38.7)  
 TVD 108 (39.4) 40 (33.6) 68 (43.9)  
Pre-TIMI flow     0.755
 0 172 (62.8) 79 (66.4) 93 (60)  
 1 15 ( 5.5) 6 (5) 9 (5.8)  
 2 25 ( 9.1) 10 (8.4) 15 (9.7)  
 3 62 (22.6) 24 (20.2) 38 (24.5)  
AHA classification     0.990
 A 2 ( 0.7) 1 (0.8) 1 (0.6)  
 B1 25 ( 9.2) 11 (9.3) 14 (9)  
 B2 38 (13.9) 17 (14.4) 21 (13.5)  
 C 208 (76.2) 89 (75.4) 119 (76.8)  
Diameter of lesion (mm) 3.0 (2.8, 3.5) 3.0 (2.8, 3.5) 3.0 (2.8, 3.5) 0.058
Length of lesion (mm) 26.0 (19.0, 37.0) 26.0 (19.0, 34.8) 26.0 (20.0, 40.0) 0.160
Endpoint events     
 MACE [%(n)] 19 (6.9) 7 (5.9) 12 (7.7) 0.718
 Death [%(n)] 2 (0.70) 0 (0) 2 (1.3) 0.507
 Recurrent MI [%(n)] 8 (2.90) 5 (4.2) 3 (1.9) 0.300
 Stroke [%(n)] 9 (3.30) 2 (1.7) 7 (4.5) 0.307
 Angina [%(n)] 21 (7.70) 8 (6.7) 13 (8.4) 0.776
 Heart failure [%(n)] 6 (2.20) 5 (4.2) 1 (0.6) 0.089
  1. Continuous data are presented as mean ± standard deviation (SD) or median (25th, 75th percentiles). Categorical data are presented as number (%)
  2. SBP, systolic blood pressure; DBP, diabetes blood pressure; PCI, percutaneous coronary intervention; CKD, chronic kidney disease; HDL, high density lipoprotein; LDL, low density lipoprotein; LPA, lipse activator; hs-CRP, high sensitive C-reactive protein; BNP, type B natriuretic peptide; WBC, White blood cell; Crea,creatinine; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; TnI, troponin; LAD, left anterior descending artery; LCX, left circumfex artery; RCA, right coronary artery; DVD, double vessel disease; SVD, single vessel disease; TVD, triple vessel disease. pre-TIMI, previous of procedural thrombolysis in myocardial infarction flow grade; AHA, American Heart Association; MACE, major adverse cardiovascular events; MI, myocardial infarction. a, TYH, defined as TyG plus LN0.01129; TyG, triglyceride glucose; A1C, Glycated hemoglobin; T, tertiles of TYG 
  3. *P < 0.05